Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
ganaplacide - Imidazolopiperazines derivative
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT04546633 KALUMI (CKAF156A2203)
Malaria, uncomplicated
Phase 2
PCR-corrected and uncorrected Adequate Clinical and Parasitological Response
(ACPR)
KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
Malaria patients 12 to < 18 years old with malaria caused by P. falciparum
H1-2022
TBD
135 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation